In Japan, approved targeted therapeutics for AD include monoclonal antibodies targeting the IL-4/IL-13 pathway, broad-acting small-molecule Janus kinase (JAK) inhibitors, and IL-31-targeting therapy, which is approved for the treatment of AD-associated itching (6, 7). The gene discussed is IL4; the disease is Alzheimer disease.